Citation Impact
Citing Papers
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
2003 Standout
Cancer statistics, 2022
2022 Standout
Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice
2023 StandoutNobel
Cancer statistics, 2023
2023 Standout
Cancer statistics, 2024
2024 Standout
Cancer treatment and survivorship statistics, 2022
2022 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
2019 Standout
Necroinflammation in Kidney Disease
2015
Paraquat Poisonings: Mechanisms of Lung Toxicity, Clinical Features, and Treatment
2007 Standout
Paraneoplastic Syndromes Involving the Nervous System
2003 Standout
Head and neck cancer
2008 Standout
Recommended diagnostic criteria for paraneoplastic neurological syndromes
2004 Standout
Molecular mechanisms of resistance and toxicity associated with platinating agents
2006 Standout
Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor
2014
Induction, Regulation, Degradation, and Biological Significance of Mammalian Metallothioneins
2000
Molecular mechanisms of cisplatin resistance
2011 Standout
Immune checkpoint inhibitors in melanoma
2021
Carcinoid A Comprehensive Review
2003
Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials
2006 Standout
Acute kidney injury
2021 Standout
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy
2007
Cisplatin: The first metal based anticancer drug
2019 Standout
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
AKT/PKB Signaling: Navigating the Network
2017 Standout
Herb-Drug Interactions
2005 Standout
Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer
2012
Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells
2018 Standout
Immune checkpoint inhibitors: recent progress and potential biomarkers
2018 Standout
Role of antioxidants in paraquat toxicity
2002 Standout
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature
2010 Standout
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Antibody-Mediated Encephalitis
2018 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Erlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future Development
2007
Head and Neck Cancer
2020 Standout
Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin
1999
Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines
2018
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
Paraneoplastic neurologic syndromes in children: a review article.
2013
Cancer treatment and survivorship statistics, 2019
2019 Standout
p53 Immunohistochemistry as a Prognostic Marker in Bladder Cancer
2000
HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory
2019
Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
2019
One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
2008 Standout
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Factors Influencing the Distribution of Metastases and Survival in Extensive Disease Small Cell Lung Cancer
1999
Hyper-Progressive Disease: The Potential Role and Consequences of T-Regulatory Cells Foiling Anti-PD-1 Cancer Immunotherapy
2020 StandoutNobel
Works of L.L. Siu being referenced
A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers
2014
Influence of age in the treatment of limited-stage small-cell lung cancer
1996
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
2017
Use of the Somatostatin Analogue Octreotide Acetate in the Treatment of Encephalopathy Associated with Carcinoid Tumor
1997
The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma.
1998
Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study.
2011
550 POSTER Dual inhibition of the MAPK pathway by combination targeted therapy: a phase I trial of sorafenib (SOR) and erlotinib (ERL) in advanced solid tumors
2006
142 Phase II study of imatinib mesylate in salivary gland adenoid cystic carcinoma
2003
Phase II, randomized, open-label study of durvalumab (MEDI4736) or tremelimumab monotherapy, or durvalumab + tremelimumab, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CONDOR
2015